Alnylam Pharmaceuticals General and Administrative Expenses 2011-2026 | ALNY

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Alnylam Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.21 B	976 M	796 M	771 M	621 M	588 M	479 M	382 M	199 M	89.4 M	60.6 M	44.5 M	27.2 M	43.7 M	38.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.21 B	27.2 M	422 M

Quarterly General and Administrative Expenses Alnylam Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
323 M	240 M	-	221 M	248 M	211 M	-	199 M	215 M	184 M	-	236 M	170 M	154 M	-	142 M	145 M	147 M	-	167 M	128 M	127 M	-	120 M	113 M	89.6 M	-	117 M	84.7 M	72.4 M	-	47.6 M	45.8 M	38.5 M	-	22.4 M	18 M	21.1 M	-	16 M	14.6 M	12.7 M	-	9.9 M	11.5 M	8.92 M	-	6.77 M	5.78 M	6.27 M	-	12.8 M	11.2 M	10.4 M	-	8.96 M	8.43 M	10.2 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
323 M	5.78 M	95.5 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Amarin Corporation plc AMRN	200 M	$ 14.81	-0.34 %	$ 6.04 B	Irlanda
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
I-Mab IMAB	900 M	-	-	$ 866 M	China
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Anavex Life Sciences Corp. AVXL	13.8 M	$ 3.93	0.26 %	$ 335 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Adagene ADAG	14.4 M	$ 3.24	13.85 %	$ 182 M	China
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Aptorum Group Limited APM	5.41 M	$ 0.79	-7.27 %	$ 4.31 M	China
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.48	-0.98 %	$ 8.37 B	Australia
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Biogen BIIB	2.43 B	$ 195.63	0.06 %	$ 28.7 B	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Aptose Biosciences APTO	11.2 M	-	-45.71 %	$ 1.2 M	Canada
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Athira Pharma ATHA	26.1 M	-	-	$ 269 M	USA
Aeglea BioTherapeutics AGLE	45.8 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Ascendis Pharma A/S ASND	160 M	$ 216.28	-0.83 %	$ 5 B	Danmark
Bristol-Myers Squibb Company BMY	7.27 B	$ 60.51	1.12 %	$ 123 B	USA
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
BioNTech SE BNTX	286 M	$ 106.24	0.45 %	$ 27.2 B	Germany
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Athersys ATHX	20.1 M	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
BeiGene, Ltd. BGNE	1.83 B	-	0.49 %	$ 251 B	Cayman-islands
Autolus Therapeutics plc AUTL	46.7 M	$ 1.41	1.81 %	$ 360 M	Britain
Burford Capital Limited BUR	99.3 M	$ 9.33	0.32 %	$ 1.51 B	Britain
Amneal Pharmaceuticals AMRX	476 M	$ 14.8	1.13 %	$ 4.57 B	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel